Skip to main content
. 2021 Jan 10;13(1):84. doi: 10.3390/pharmaceutics13010084

Figure 8.

Figure 8

Survival curves (MTT assay) of triple negative breast cancer cell lines MDA-MB-231 (A) and MDA-MB-231PAC10 (B) after 72 h of exposure to increasing concentration of DDC-Cu formulations. (C) The IC50 values of DDC-Cu and formulations on both breast cancer cell lines (n = 3 ± SD).